Littlewood J D, Barrowcliffe T W
Department of Clinical Veterinary Medicine, University of Cambridge, UK.
Thromb Haemost. 1987 Jun 3;57(3):314-21.
Four haemophilic dogs received infusions of human factor VIII concentrates, and developed inhibitors to human F VIII. These inhibitors cross-reacted with canine F VIII with parallel increases and decreases in titre. Cross-reaction was also found to porcine F VIII but changes in titre did not correlate with anti-human and anti-canine titres. These inhibitors were found to be immunoglobulins, and antibodies were detected against other proteins found in concentrates. Kinetic studies showed that in all four dogs the F VIII inhibitors were Type II antibodies. One of the dogs behaved as a "high-responder", whilst another was more analogous to a "low-responder" patient. Phospholipid protection experiments in vitro demonstrated that some antibodies could be prevented from inhibiting F VIII, and porcine F VIII was particularly well protected against inhibition.
四只血友病犬接受了人凝血因子VIII浓缩物输注，并产生了针对人F VIII的抑制剂。这些抑制剂与犬F VIII发生交叉反应，效价平行上升和下降。还发现与猪F VIII有交叉反应，但效价变化与抗人及抗犬效价不相关。这些抑制剂被发现是免疫球蛋白，并且检测到针对浓缩物中其他蛋白质的抗体。动力学研究表明，在所有四只犬中，F VIII抑制剂均为II型抗体。其中一只犬表现为“高反应者”，而另一只则更类似于“低反应者”患者。体外磷脂保护实验表明，一些抗体可被阻止抑制F VIII，并且猪F VIII对抑制具有特别好的保护作用。
